RVSV-ZEBOV vaccine
RVSV-ZEBOV vaccine
The RVSV-ZEBOV vaccine (pronounced as /ɑːr viː ɛs viː zɛbɔːv/) is a vaccine developed for the prevention of the Ebola virus disease, a severe and often fatal illness in humans.
Etymology
The name "RVSV-ZEBOV" is an acronym derived from the components of the vaccine. "RVSV" stands for "Recombinant Vesicular Stomatitis Virus", which is the virus used as a vector in the vaccine. "ZEBOV" stands for "Zaire Ebola Virus", which is the specific strain of Ebola that the vaccine is designed to protect against.
Usage
The RVSV-ZEBOV vaccine is used in individuals aged 18 years and older, and is administered as a single dose. The vaccine has been shown to be effective in preventing infection in individuals who are at risk of exposure to the Ebola virus.
Development
The RVSV-ZEBOV vaccine was developed by the Public Health Agency of Canada and is currently licensed to Merck & Co.. The vaccine was first tested in humans in 2014 during the West Africa Ebola outbreak, and was found to be highly effective in preventing Ebola virus disease.
Related Terms
External links
- Medical encyclopedia article on RVSV-ZEBOV vaccine
- Wikipedia's article - RVSV-ZEBOV vaccine
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski